FHIR © HL7.org  |  FHIRsmith 4.0.1  |  Server Home  |  XIG Home  |  XIG Stats  | 

FHIR IG analytics

Packageke.fhir.nccp
Resource TypeMedicationStatement
IdMedicationStatement-PriorSystemicTherapyStatementExample.json
FHIR VersionR4

Resources that use this resource

No resources found


Resources that this resource uses

No resources found


Narrative

Note: links and images are rebased to the (stated) source

5 years of adjuvant tamoxifen for ER+ breast cancer (2018–2023) prior to current recurrence


Source1

{
  "resourceType": "MedicationStatement",
  "id": "PriorSystemicTherapyStatementExample",
  "meta": {
    "profile": [
      "https://nshr-uat.sha.go.ke/fhir/StructureDefinition/nccp-prior-systemic-therapy-statement"
    ]
  },
  "text": {
    "status": "generated",
    "div": "<!-- snip (see above) -->"
  },
  "status": "completed",
  "category": {
    "coding": [
      {
        "system": "https://nshr-uat.sha.go.ke/fhir/CodeSystem/med-clinical-category-cs",
        "code": "HORMONAL-THERAPY",
        "display": "Hormonal Therapy"
      }
    ]
  },
  "medicationCodeableConcept": {
    "coding": [
      {
        "system": "https://nshr-uat.sha.go.ke/fhir/CodeSystem/generic-products-cs",
        "code": "TAMOXIFEN",
        "display": "Tamoxifen"
      }
    ]
  },
  "subject": {
    "reference": "Patient/example-patient"
  },
  "effectivePeriod": {
    "start": "2018-03-01",
    "end": "2023-02-28"
  },
  "reasonReference": [
    {
      "reference": "Condition/example-condition"
    }
  ],
  "note": [
    {
      "text": "Completed 5 years of adjuvant tamoxifen. Switched to letrozole following menopause in 2021."
    }
  ]
}